Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000751 · ClinicalTrials.gov registry record · Phase 3
A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)
A Phase 3 study of HIV Infections and Pregnancy, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- Completed
- Registry status
- Phase 3
- Development phase
- 1,600
- Enrollment target
- 20
- Study locations
NCT00000751: Completed Phase 3 study of HIV Infections and Pregnancy, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
NCT00000751 is a Phase 3 study of HIV Infections and Pregnancy that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 1,600 participants, above the 443-participant average among 542 other HIV Infections trials with a reported enrollment target (261% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000751, a Phase 3 study of HIV Infections and Pregnancy, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,600 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the effect of anti-HIV immune serum globulin (HIVIG) versus immune globulin (IVIG) administered during pregnancy and to the newborn, in combination with zidovudine (AZT) administered intrapartum and to the newborn, on incidence of HIV infection in infants born to HIV-infected women who received AZT during pregnancy for medical indications. Vertical transmission of HIV from mother to child may occur before, during, or after parturition (via breast-feeding). It is believed that therapy administered both during pregnancy and intrapartum may help prevent vertical transmission. Additionally, adjunctive short-term antiretroviral therapy for the newborn, following the intensive viral exposure presumed to occur at birth, may be necessary.
Conditions Studied
Interventions
- DRUG Zidovudine
- DRUG Anti-HIV Immune Serum Globulin (Human)
- DRUG Globulin, Immune
Study Locations (20)
California
- UCSD Med Ctr / Pediatrics / Clinical Sciences - La Jolla
- Los Angeles County - USC Med Ctr - Los Angeles
- UCLA Med Ctr / Pediatric - Los Angeles
- Harbor - UCLA Med Ctr / UCLA School of Medicine - Los Angeles
- San Francisco Gen Hosp - San Francisco
- UCSF / Moffitt Hosp - Pediatric - San Francisco
District of Columbia
- Children's Hosp of Washington DC - Washington D.C.
- Washington Hosp Ctr - Washington D.C.
- Howard Univ Hosp - Washington D.C.
Colorado
- Denver Gen Hosp - Denver
- Children's Hosp of Denver - Denver
Florida
- Univ of Florida Health Science Ctr / Pediatrics - Jacksonville
- Univ of Miami (Pediatric) - Miami
Louisiana
- Tulane Univ / Charity Hosp of New Orleans - New Orleans
- Univ Hosp - New Orleans
Maryland
- Univ of Maryland at Baltimore / Univ Med Ctr - Baltimore
- Johns Hopkins Hosp - Pediatric - Baltimore
Connecticut
- Univ of Connecticut / Farmington - Farmington
Illinois
- Univ of Illinois College of Medicine / Pediatrics - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,600 participants |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)305 total trials
What the finished NCT00000751 record still lists
NCT00000751 is an interventional study that assigns participants to a tested intervention. Its 1,600 participants enrollment target places it among the larger protocols in the corpus, above the 443-participant average among 542 other HIV Infections trials with a reported enrollment target (261% higher).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Zidovudine is the first listed.
NCT00000751 names 20 study sites across 9 states, led by California, District of Columbia, Colorado.
Frequently Asked Questions
What is clinical trial NCT00000751 about?
NCT00000751 is a clinical study titled "A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)". To evaluate the effect of anti-HIV immune serum globulin (HIVIG) versus immune globulin (IVIG) administered during pregnancy and to the newborn, in combination with zidovudine (AZT) administered intrapartum and to the newborn, on incidence of HIV infection in infants born to HIV-infected women who r...
What is the current status of trial NCT00000751?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,600 participants. Estimated completion is 2007-08.
What conditions does trial NCT00000751 study?
This clinical trial studies the following conditions: HIV Infections, Pregnancy.
What interventions are being tested in trial NCT00000751?
The interventions under investigation include: Zidovudine (DRUG), Anti-HIV Immune Serum Globulin (Human) (DRUG), Globulin, Immune (DRUG).
Who is sponsoring clinical trial NCT00000751?
This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000751 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000751's enrollment target sits among peer trials
1,600 15th of 542 higher than 528 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- NCT04314401 · 1,600 participants
National Cancer Institute "Cancer Moonshot Biobank"